- Invst Guru
- Posts
- The Technology Changing Addiction Treatment: Inside Berkshire Biomedical’s Breakthrough
The Technology Changing Addiction Treatment: Inside Berkshire Biomedical’s Breakthrough
A closer look at how COPATM could reshape secure medication management and what’s next.
In partnership with
Crowdfunding Has Never Been This Easy
Invst Guru is your bi-weekly digest that explores the dynamics of equity crowdfunding. Delivered every Wednesday and Sunday, we connect startups with the power of the crowd, providing investors with access to groundbreaking ventures.
In each issue of Invst Guru, we'll spotlight the latest trends, share success stories, and offer insights from industry leaders. We aim to equip you with the knowledge and opportunities to participate effectively in equity crowdfunding, whether you're looking to fund your innovative startup or invest in potential unicorns.
Today’s Sponsor 💰
Today’s Fastest Growing Company Might Surprise You
🚨 No, it's not the publicly traded tech giant you might expect… Meet $MODE, the disruptor turning phones into potential income generators.
Mode saw 32,481% revenue growth, ranking them the #1 software company on Deloitte’s 2023 fastest-growing companies list.
📲 They’re pioneering "Privatized Universal Basic Income" powered by technology — not government, and their EarnPhone has already helped consumers earn over $325M!
Invest in their pre-IPO offering before their share price changes on May 1st.
*An intent to IPO is no guarantee that an actual IPO will occur. Please read the offering circular and related risks at invest.modemobile.com.
*The Deloitte rankings are based on submitted applications and public company database research.
🔹 Deal in Focus: Berkshire Biomedical Pioneering Secure Medication Management
"A future where patients can manage opioid treatment safely from home? Berkshire Biomedical is working to make that vision a reality."
🔍 The Big Picture
Berkshire Biomedical, a Dallas-based medical technology innovator, is addressing an urgent need: enabling secure, personalized medication management from the comfort of home.
Their flagship product, COPA™, uses dual biometrics and remote monitoring to deliver a new level of trust and safety for patients battling Opioid Use Disorder (OUD).
🔹 The Problem They’re Tackling
The opioid crisis remains staggering:
5.7 million Americans live with OUD.
Only 20% receive medication-assisted treatment.
Traditional clinic models are costly, cumbersome, and often discourage adherence.
There’s an urgent need for better, tech-enabled at-home solutions.
🔹 The Berkshire Biomedical Approach
COPA™ (Controlled Oral Prescription Administration) introduces:
Dual Biometric Authentication: Fingerprint + dentition scan required for every dose.
Remote Monitoring: Real-time dosage reporting to providers.
Secure Liquid Dispensing: Reducing errors and diversion risk.
"Better access, coupled with more accountability, can improve outcomes across the OUD treatment spectrum." — John Timberlake, CEO
🔹 Technology Overview
19 Issued Patents
HIPAA-compliant cloud architecture
Secure locking mechanisms
Modular, multi-medication adaptability
Berkshire isn’t just building a dispenser; they’re creating a digital trust network for medication adherence.
🔹 Market Opportunity
OUD treatment market projected to reach billions by 2032.
Telehealth adoption is accelerating post-pandemic.
Methadone access bottlenecks create an opportunity for secure, remote solutions.
COPA™ may be positioned to enable a paradigm shift in outpatient care.
🔹 Business Context & Progress
Recent milestones:
$2M NIH grant awarded
FDA pre-submission meetings completed
Prototype validation field-tested
Peer-reviewed research published
🔹 Product Development Roadmap
2024: Final validation and additional NIH grants
2025: Launch initial clinical studies
2026: Commercial launch (pending FDA approval)
Beyond 2026: Expansion into chronic pain, oncology, and palliative care sectors
⚠️ Forward-Looking Disclaimer:
Future plans are based on current expectations and involve risks and uncertainties. Actual results may differ materially.
🔹 Leadership Team
John Timberlake — CEO, President, CFO (30+ years in life sciences)
Christy Corey — Head of Operations (FinTech + operations expertise)
Thomas Rouse — Founder, Chairman (serial entrepreneur)
🔹 Why It Matters
The opioid epidemic demands innovation.
Berkshire Biomedical's secure, tech-driven solution could transform how addiction — and chronic disease management more broadly — is treated in the U.S.
🔹 Key Risks
FDA approval risk
Market adoption challenges
Financial needs as a pre-revenue company
Emerging competition in the digital health space
🔹 Final Thoughts
Berkshire Biomedical is a mission-driven innovation story at the intersection of healthtech and social impact.
For those passionate about addressing critical healthcare gaps, their journey is one to watch, but it comes with serious risks.
Would You Invest in BERKSHIRE BIOMEDICAL? |
🔹 Learn More
🧩 Visit Berkshire Biomedical’s official StartEngine campaign page here to review full offering documents, risk factors, and disclosures.
⚠ Securities Disclaimer:
Berkshire Biomedical is currently conducting a Regulation Crowdfunding (Reg CF) offering. All investments must be made through the StartEngine platform, a registered intermediary. Investing in startups involves significant risk, including the potential loss of your entire investment.
Last Issues Poll Results 🗳️:
Would You Invest In HardAF Seltzer?
🟨🟨🟨⬜️⬜️⬜️ 👍 (3)
🟨🟨⬜️⬜️⬜️⬜️ 👎 (2)
🟩🟩🟩🟩🟩🟩 🤷 (5)
10 Votes
📰 Are you thinking about starting your newsletter? If so, use Beehiiv, like we do. 📰